1. Introduction {#sec1-molecules-23-02112}
===============

*Euphorbia maculata* L. is a plant of the Euphorbiaceae family, which is widely used as folk medicine throughout the world, especially in China, Japan, and Korea \[[@B1-molecules-23-02112]\]. Many species of the genus *Euphorbia* have a variety of applications in traditional Chinese medicines (TCM). *E. maculata* is an annual herb that is commonly used for the treatment of diarrhea, hemoptysis, hematuria, and sore swollen \[[@B2-molecules-23-02112]\]. Extracts of this plant has an antiplatelet activity via suppressing thromboxane B2 formation \[[@B3-molecules-23-02112]\]. Previous phytochemical investigations of *E. maculata* yielded tannins, flavonol glycoside, and triterpenoids \[[@B4-molecules-23-02112],[@B5-molecules-23-02112],[@B6-molecules-23-02112],[@B7-molecules-23-02112]\].

Naturally occurring triterpenoids possesses anti-tumor, anti-inflammatory, anti-proliferative, and anti-HIV activities. Many triterpenoids of different skeletons exhibited anti-inflammatory and inhibitory activities on tumor promotion induced by TPA \[[@B8-molecules-23-02112],[@B9-molecules-23-02112],[@B10-molecules-23-02112]\]. As many tumor promoters can cause inflammatory symptoms, the inhibitory effect against TPA-induced ear inflammation has a close correlation with the inhibition of TPA-induced tumor promotion in a two-stage carcinogenesis. Thus, we chose the medicinal plants of the genus *Euphorbia* (Euphorbiaceae) which contained triterpenoids to study their chemical constituents and pharmacological activity \[[@B11-molecules-23-02112]\]. We found that the lanostane-type triterpenes of *E. kansui* markedly possessed the inhibitory activity against TPA-induced inflammation, and the predominant triterpene in this plant, euphol, significantly inhibited the tumor-promoting activity induced by TPA \[[@B12-molecules-23-02112]\].

In the course of our continuing search for anti-inflammatory compounds from plants \[[@B13-molecules-23-02112],[@B14-molecules-23-02112],[@B15-molecules-23-02112],[@B16-molecules-23-02112]\], we focused on the *Euphorbia maculata* due to their medicinal use and began to clarify their anti-inflammatory principles. Herein, we describe the structural elucidation of the new triterpenoids and the anti-inflammatory activities of all tetracyclic isolated triterpenoids.

2. Results and Discussion {#sec2-molecules-23-02112}
=========================

2.1. Triterpenoids of Euphorbia maculata {#sec2dot1-molecules-23-02112}
----------------------------------------

We investigated the *n*-hexane extract of *E. maculata* by the bioassay-guided fractionation method. Seventeen triterpene derivatives (**1**--**17**) ([Figure 1](#molecules-23-02112-f001){ref-type="fig"}), including a new spiro-triterpenoid (**1**) and a new lanostane triterpenoid (**2**), were isolated. Compounds **3**--**17** were identified to be 3-hydroxycycloart-25-ene-24-hydroperoxide (**3**) \[[@B17-molecules-23-02112]\], 3β-hydroxy-26-nor-9,19-cyclolanost-23-en-25-one (**4**) \[[@B18-molecules-23-02112]\], cycloart-23en-3β,25-diol (**5**) \[[@B19-molecules-23-02112]\], (23*E*)-3β,25-dihydroxytirucalla-7,23-diene (**6**) \[[@B20-molecules-23-02112]\], (23*Z*)-3β,25-dihydroxy-tirucalla-7,23-diene (**7**) \[[@B21-molecules-23-02112]\], Obtusifoliol (**8**) \[[@B22-molecules-23-02112]\], cycloeucalenol (**9**) \[[@B23-molecules-23-02112]\], 4α,l4α-dimethyl-5α-ergosta-7,9(11),24(28)-trien-3β-ol (**10**) \[[@B24-molecules-23-02112]\], gramisterol (**11**) \[[@B25-molecules-23-02112]\], urs-12-ene-3β,11α-diol (**12**) \[[@B26-molecules-23-02112]\], Neoilexonol (**13**) \[[@B27-molecules-23-02112]\], 12-Oleanene-3β,11β-diol (**14**) \[[@B28-molecules-23-02112]\], (3β,15α,16α)-15,16-epoxy-Olean-12-en-3-ol (**15**) \[[@B29-molecules-23-02112]\], lupeol (**16**) \[[@B30-molecules-23-02112]\], multiflorenol (**17**) \[[@B31-molecules-23-02112]\] by compared spectroscopic data and physicochemical properties with those reported in the literatures. The new compounds were determined by means of mass spectrometry and extensive 1D and 2D NMR.

2.2. Structures {#sec2dot2-molecules-23-02112}
---------------

Compound **1** was isolated as a white solid. Its HREIMS spectrum showed a molecular ion peak at *m*/*z* 458.3759 \[M^+^\], corresponding to the molecular formula C~30~H~50~O~3~. The ^1^H-NMR (Table 2, [Figure S1](#app1-molecules-23-02112){ref-type="app"}) displayed characteristic signals for seven methyl groups \[*δ*~H~ 0.66 (3H, s), 0.93 (3H, d, *J* = 6.5 Hz), 0.95 (3H, d, *J* = 6.2 Hz), 1.02 (3H, d, *J* = 6.7 Hz), 1.03 (3H, d, *J* = 6.8 Hz), 1.21 (3H, s), 1.48 (3H, s)\], two oxygenated methine protons \[*δ*~H~ 3.05 (1H, td, *J* = 10.0, 4.8 Hz) and 4.35 (1H, m)\], and two olefinic protons \[*δ*~H~ 4.66 (1H, d, *J* =1.2 Hz) and 4.72 (1H, d, *J* = 0.9 Hz)\]. The ^13^C-NMR (Table 2, [Figure S2](#app1-molecules-23-02112){ref-type="app"}) and HMQC spectra ([Figure S3](#app1-molecules-23-02112){ref-type="app"}) disclosed the existence of thirty carbons including a ketone (*δ*~C~ 215.1), two olefins (*δ*~C~ 156.5 and 106.2), and two oxygenated methines (*δ*~C~ 80.5 and 77.5). The aforementioned data suggested that **1** was a triterpenoid ([Figure 2](#molecules-23-02112-f002){ref-type="fig"}). In the ^1^H-^1^H COSY spectrum ([Figure S5](#app1-molecules-23-02112){ref-type="app"}), five fragments were obtained according to the spin systems of H~2~-1/H~2~-2/H-3/H-4/H-5/H~2~-6/H-7, H~2~-11/H~2~-12, H~2~-15/H~2~-16/H-17, H~3~-21/H-20/H~2~-22/H~2~-23, and H-25/ H~3~-26/ H~3~-27. The HMBC correlations ([Figure S4](#app1-molecules-23-02112){ref-type="app"}) from H-4 and H~3~-29 to C-3, and from H~2~-6 and H~2~-11 to C-7 indicated that the two hydroxyl groups were located at C-3 and C-7, respectively. Furthermore, the HMBC correlations from both H~3~-19 and H~2~-6 to C-5, C-9, C-10, and from H-7 to C-5, C-9 and C-10, as well as the ^1^H-^1^H COSY cross-peaks of H~2~-6/H-7 and H~2~-11/H~2~-12 suggested that the quaternary carbon C-9 was the connectivity of a spiro center. The ketone group was substituted at C-8, which was indicated by the HMBC correlations from H~3~-30 to C-8, C-13, and C-14, and from H~2~-11 to C-8. The EIMS of **1** displayed two characteristic peaks of spiro-triterpenoid at 319.2 \[C~21~H~35~O~2~\] and 219.2 \[C~16~H~27~\], together with *m*/*z* 440 \[M − H~2~O\]^+^ and 422 \[M − 2H~2~O\]^+^. The relative configuration of **1** was determined by NOESY spectrum ([Figure 2](#molecules-23-02112-f002){ref-type="fig"}, [Figure S6](#app1-molecules-23-02112){ref-type="app"}). The NOESY correlations between H~3~-19 and H-2β, H-6β, and H~3~-18 indicated that these protons were at the same orientation. Furthermore, the orientations of the two hydroxyl groups were deduced as β on the basis of the NOE correlations between H-7 and H-5α, H-11α, and H~3~-30, and between H-3 and H-5α, and H~3~-29. The above NOE correlations also suggested that C-9 was *R* configuration. The C-ring was supposed to be a boat configuration based on the NOE correlations of H-5α with H-11β and H-17α with H~3~-30, which was the same as that of spiroinonotsuoxodiol. Based on the comparison of its NMR data with that of a spiro-triterpene in the literature \[[@B32-molecules-23-02112]\], the structure of **1** was determined to be (3*S*,4*S*,7*S*,9*R*)-4-methyl-3,7-dihydroxy-7(8→9) *abeo*-lanost-24(28)-en-8-one ([Figure 1](#molecules-23-02112-f001){ref-type="fig"}).

Compound **2** was obtained as a white solid. The molecular formula of **2** was determined to be C~30~H~50~O~3~ (\[M\]^+^ *m*/*z* 458.3755; Calcd. 458.3760) on the basis of HREIMS and NMR data. The ^1^H-NMR spectrum (Table 2, [Figure S7](#app1-molecules-23-02112){ref-type="app"}) exhibited six methyl singlets at *δ*~H~ 0.75 (3H, s), 0.81 (3H, s), 0.86 (3H, s), 0.98 (6H, s), 1.73 (3H, s), a methyl group doublets at *δ*~H~ 0.75 (3H, d, *J* = 7.4 Hz), two oxygenated methine protons at *δ*~H~ 3.24 (1H, dd, *J* = 11.7, 4.6 Hz) and 4.21 (1H, t, *J* = 8.0 Hz), and two olefinic protons at *δ*~H~ 5.02 (1H, m) and 5.26 (1H, dd, *J* = 7.6, 3.3 Hz). Analysis the ^13^C-NMR (Table 2, [Figure S8](#app1-molecules-23-02112){ref-type="app"}) and HMQC spectra ([Figure S9](#app1-molecules-23-02112){ref-type="app"}) displayed signals corresponding to six quaternary carbons, including two olefinic (*δ*~C~ 145.7, 143.8) and four aliphatic carbons (*δ*~C~ 34.9, 38.9, 43.5, 51.1), ten methylene groups with corresponding carbons between *δ*~C~ 18.1 and *δ*~C~ 37.2, a further olefinic group at *δ*~C~ 114.2, seven methine groups at *δ*~C~ 36.0--117.8, and seven methyl groups at *δ*~C~ 13.1--27.7. These NMR data suggested that **2** was a lanostane-type triterpenoid \[[@B33-molecules-23-02112]\]. The HMBC correlations ([Figure S10](#app1-molecules-23-02112){ref-type="app"}) from H~2~-1, H-5 and H~3~-28 to C-3 indicated that an -OH group was present at C-3 (*δ*~C~ 79.7) ([Figure 2](#molecules-23-02112-f002){ref-type="fig"}). The HMBC correlations from H-5 to C-7, and from H~2~-11 to C-8 confirmed a double bond at C-7 (*δ*~C~ 117.8) and C-8 (*δ*~C~ 145.7). HMBC correlations from H~2~-23, H~2~-26 and H-27 to C-24 and chemical shifts of C-24 (*δ*~C~ 90.1 and *δ*~H~ 4.21) suggested that a hydroperoxy group was located at C-24. The NOESY spectrum of **2** exhibited correlations between H-3α and H-5α, and between H-5α and H-6α, supporting the β-orientation of the 3-OH group ([Figure 2](#molecules-23-02112-f002){ref-type="fig"}, [Figure S12](#app1-molecules-23-02112){ref-type="app"}). The NOESY correlations between H~3~-30 and H-17α, and between H-17α and H~3~-21 indicated that H-17 was α-oriented and C-20 was *R* configuration. Therefore, compound **2** was determined to be 24-hydroperoxylanost-7, 25-dien-3β-ol, whose structure is similar to **3** ([Figure 1](#molecules-23-02112-f001){ref-type="fig"}).

2.3. Anti-Inflammatory {#sec2dot3-molecules-23-02112}
----------------------

The *n*-hexane extract of the whole plant of *E. maculata* inhibited the inflammatory ear oedema induced by TPA with the ID~50~ (50% inhibitory dose) value of 0.8 mM. All the tetracyclic triterpenoids were evaluated with respect to their anti-inflammatory activity against TPA-induced inflammation in mice, and the inhibitory effects were compared with indomethacin, a commercially available anti-inflammatory drug, as shown in [Table 1](#molecules-23-02112-t001){ref-type="table"}. Most of the tetracyclic triterpenoids exhibited a potent inhibitory activity, with ID~50~ values in the range of 87.1--1087 nM/ear, of which compound **8** showed the most potent inhibitory activity higher than indomethacin (ID~50~ 838 nM/ear). The results indicated that compounds **8**, **10**, and **11** with only one methyl substitution at C-4 and a double bond at C-24 in the side chain possessed a stronger anti-inflammatory activity than the other tetracyclic triterpenoids.

Another tetracyclic triterpene, euphol isolated from *E. kansui* possessed both anti-inflammatory and anti-tumor promoting activities. Various triterpenoids of different skeletons have been demonstrated to inhibit the tumor-promoting activities induced by TPA. The inhibitory activity of euphol was similar to lupeol (**16**) \[[@B34-molecules-23-02112]\]. Thus, we concluded that most triterpenes isolated from *E. maculata* probably inhibited the tumor-promoting activity by TPA.

3. Materials and Methods {#sec3-molecules-23-02112}
========================

3.1. General Experimental Procedures {#sec3dot1-molecules-23-02112}
------------------------------------

Optical rotations were measured on a Jasco DIP-360 polarimeter. UV spectrum was obtained on a Jasco V-550 spectraphotometer (Tokyo, Japan). FAB-MS and HR-FAB-MS were obtained using a JEOLJMS-GC mate spectrometer (JEOL, Tokyo, Japan). NMR spectra were recorded using a JEOL ECA 600 spectrometer (JEOL, Tokyo, Japan), with TMS as an internal standard. Silica gel (230--400 mesh, Merck, Darmstadt, Germany) and Silica gel plates (GF~254~, Merck, Darmstadt, Germany) were used for CC and TLC, respectively. Sephadex LH-20 was purchased from Pharmacia (Uppsala, Sweden). ODS-EP column (250 × 10 mm, Inertsil; GL sciences Inc., Tokyo, Japan) was used for preparative HPLC.

3.2. Plant Material {#sec3dot2-molecules-23-02112}
-------------------

The dried whole plant of *Euphorbia maculata* was collected in Medicinal Plant Garden of College of Pharmacy, Nihon University. The plant was authenticated by Prof. Yasukawa, College of Pharmacy, Nihon University, Chiba, Japan. A voucher specimen has been deposited in the College of Pharmacy, Nihon University, Chiba, Japan.

3.3. Extraction and Isolation {#sec3dot3-molecules-23-02112}
-----------------------------

The dried whole plant of *E. maculata* (1.5 kg) was ground and extracted with MeOH (3 L × 24 h × 5) at room temperature. After the combined extract was evaporated under reduced pressure at 40 °C, the residue (32.6 g) was suspended in H~2~O and then partitioned with EtOAc. The EtOAc-soluble extract (14.0 g) was partitioned with *n*-hexane--MeOH--H~2~O (19:19:2), giving *n*-hexane- (13.0 g) and MeOH--H~2~O (0.9 g) soluble fractions. The H~2~O fraction was partitioned between *n*-BuOH--H~2~O (1:1), yielding *n*-BuOH (5.9 g) and H~2~O (8.3 g) fractions.

The *n*-hexane extract was subjected to a silica gel column, eluting with a gradient of *n*-hexane/EtOAc, and then monitored on TLC to obtain five major fractions. Fraction 3 (4.8 g) was chromatographed over a silica gel column (eluting with PE/acetone), resulting in six fractions (fr. 4.1--4.6). Fraction 4.2 was further purified by Sephadex LH-20 and reversed-phase HPLC (75--85% ACN/H~2~O) to afford **1** (3 mg). Fraction 4.3 was separated by reversed-phase HPLC (70--90% ACN/H~2~O), yielding **2** (2 mg), **3** (3 mg), **4** (5 mg), **5** (1 mg), **6** (4 mg), **7** (4 mg), **13** (7 mg), and **14** (12 mg). Fraction 4.4 was purified by reversed-phase HPLC (70--85% ACN/H~2~O) to give **8** (2 mg), **9** (2 mg), **12** (5 mg), **15** (4 mg), and **16** (3 mg). Fraction 4 (3.6 g) was isolated by HPLC (70--85%ACN/H~2~O) to yield **10** (5 mg) and **11** (7 mg).

### 3.3.1. Compound **1** {#sec3dot3dot1-molecules-23-02112}

White solid. \[a\]${}_{D}^{20}$: −35.5 (*c* 0.1, CHCl~3~). HREIMS *m*/*z*: 458.3759 \[M\]^+^ (C~30~H~50~O~3~, calcd for 458.3760). EIMS *m*/*z*: 458 \[M\]^+^, 440 \[M − H~2~O\]^+^, 425 \[M − H~2~O − Me\]^+^. ^1^H and ^13^C-NMR spectroscopic data, see [Table 2](#molecules-23-02112-t002){ref-type="table"}. All NMR spectra of **1** have been provided in the [Supplementary Material](#app1-molecules-23-02112){ref-type="app"}.

### 3.3.2. Compound **2** {#sec3dot3dot2-molecules-23-02112}

White solid. \[a\]${}_{D}^{20}$: +4.2 (*c* 0.1, CHCl~3~). HREIMS *m*/*z*: 458.3755 \[M\]^+^ (C~30~H~50~O~3~, calcd for 458.3760). EIMS *m*/*z*: 458 \[M\]^+^, 443 \[M − Me\]^+^, 425 \[M − Me − H~2~O\]^+^, 407 \[M − Me − 2H~2~O\]^+^. ^1^H and ^13^C-NMR spectroscopic data, see [Table 2](#molecules-23-02112-t002){ref-type="table"}. All NMR spectra of **2** have been provided in the [Supplementary Material](#app1-molecules-23-02112){ref-type="app"}.

3.4. Biological Assay {#sec3dot4-molecules-23-02112}
---------------------

### 3.4.1. Animals {#sec3dot4dot1-molecules-23-02112}

Experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the College of Pharmacy, Nihon University, Chiba, Japan. Female ICR mice were purchased from Japan SLC Inc., Shizuoka, Japan, and housed in an air-conditioned specific pathogen free room (22--23 °C) lit from 08:00 to 22:00. Food and water were available *ad libitum*.

### 3.4.2. Assay of TPA Inflammation Ear Edema in Mice {#sec3dot4dot2-molecules-23-02112}

TPA (1.7 nmol, 1 μg) dissolved in acetone (20 μL) was applied to the right ear only of ICR mice by means of a micropipette. A volume of 10 μL was delivered to both the inner and outer surface of the ear. The samples or their vehicles, CHCl~3~/MeOH (1:1, 20 μL), as a control, were applied topically about 30 min before TPA treatment. For ear thickness determinations, a pocket thickness gauge with a range of 0--9 mm, graduated at 0.01 mm intervals and modified so that the contact surface area was increased to reduce the tension, was applied to the tip of the ear. The ear thickness was measured before treatment (*a*) and 6 h after TPA treatment (*b* = TPA alone; *b*' = TPA plus sample). The following values were then calculated:Edema A as induced by TPA alone (*b*--*a*)Edema B as induced by TPA plus sample (*b*'--*a*)Inhibitory ratio (IR) (%) = \[(Edema A − Edema B)/Edema A\] × 100Each value was the mean of individual determinations from five mice. The 50% inhibitory dose (ID~50~) values were determined by the method of probit-graphic interpolation for four dose levels.

4. Conclusions {#sec4-molecules-23-02112}
==============

In this study, we isolated two new lanostane-type triterpennes, together with 15 known triterpenoids. We evaluated the anti-inflammatory activities of all the tetracyclic triterpenoids. Triterpenoids 1--11 isolated from *E. maculata* exhibited potent anti-inflammatory activities. Many triterpenes with different skeletons, such as oleanae-, ursane-, lupine-, lanostane-, and multiflorane-types, inhibited the tumor promoting activity of TPA. Therefore, these triterpenes might be the candidates for cancer chemopreventive agents.
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HREIMS, 1D (^1^H-NMR, ^13^C-NMR, and DEPT spectra), and 2D (HMQC, ^1^H-^1^H COSY, HMBC, and NOESY spectra) NMR spectra of new compounds **1** and **2** were available online.
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![The chemical structures of compounds **1**--**17** isolated from *Euphorbia maculata.*](molecules-23-02112-g001){#molecules-23-02112-f001}

![(**a**) Key HMBC correlations and EIMS of **1**; (**b**) Key NOESY correlations of **1**.](molecules-23-02112-g002){#molecules-23-02112-f002}

molecules-23-02112-t001_Table 1

###### 

Inhibitory effects of triterpenoids on TPA-induced inflammation in mice.

  Compounds                                                             ID~50~ ^a^ (nM/ear)   Range
  --------------------------------------------------------------------- --------------------- --------------
  4-methyl-3,7-dihydroxy-7(8→9) *abeo*-lanost-24(28)-en-8-one (**1**)   803                   624--1035
  24-hydroperoxylanost-7,25-dien-3β-ol (**2**)                          356.3                 280.8--452.3
  3-hydroxycycloart-25-ene-24-hydroperoxide (**3**)                     301.7                 212.0--429.3
  3β-hydroxy-26-nor-9,19-cyclolanost-23-en-25-one (**4**)               558                   462--836
  cycloart-23-en-3β,25-diol (**5**)                                     355.7                 276.2--458.1
  (23*E*)-3β,25-dihydroxytirucalla-7,23-diene (**6**)                   855                   644--1134
  (23*Z*)-3β,25-dihydroxy-tirucalla-7,23-diene (**7**)                  1087                  809--1460
  Obtusifoliol (**8**)                                                  87.1                  36.8--206.4
  cycloeucalenol (**9**)                                                463.9                 345.4--623.0
  4α,l4α-dimethyl-5α-ergosta-7,9(11),24(28)-trien-3β-ol (**10**)        363.1                 273.7--481.6
  gramisterol (**11**)                                                  204                   86.1--484
  Indomethacin ^b^                                                      838.0                 730--945

^a^ ID~50~: The 50% inhibitory dose. ^b^ Reference compound.

molecules-23-02112-t002_Table 2

###### 

^1^H and ^13^C-NMR Data of compounds **1** and **2** (600 MHz and 150 MHz in CDCl~3~).

  ------------------------------------------------------------------------------------------------------
  Pos.     1              2                                              
  -------- -------------- ------------------------------- -------------- -------------------------------
  **1**    30.1, CH~2~    1.59 (m)                        37.2, CH~2~    1.13 (m)\
                                                                         1.69 (m)

  **2**    30.8, CH~2~    1.70 (m)\                       27.6, CH~2~    1.65 (m)
                          1.83 (m)                                       

  **3**    77.0, CH       3.05 (td, *J =* 10.0, 4.8 Hz)   79.2, CH       3.24 (dd, *J* = 11.7, 4.6 Hz)

  **4**    38.1, CH       1.66 (m)                        38.9, C        

  **5**    48.2, CH       1.21 (m)                        50.6, CH       1.32 (m)

  **6**    37.8, CH~2~    1.37 (m)\                       23.9, CH~2~    1.94 (m)\
                          2.39 (m)                                       2.15 (m)

  **7**    80.5, CH       4.35 (m)                        117.8, CH      5.26 (dd, *J* = 7.6, 3.3 Hz)

  **8**    215.1, C                                       145.7, C       

  **9**    64.0, C                                        48.9, CH       2.21 (m)

  **10**   48.1, C                                        34.9, C        

  **11**   28.7, CH~2~    1.41 (m)                        18.1, CH~2~    0.99 (m)\
                                                                         1.52 (m)

  **12**   30.1, CH~2~    1.61 (m)\                       33.7, CH~2~    1.61 (m)\
                          1.78 (m)                                       1.80 (m)

  **13**   47.6, C                                        43.5, C        

  **14**   61.0, C                                        51.1, C        

  **15**   29.5, CH~2~    1.23 (m)\                       33.9, CH~2~    1.46 (m)
                          2.0 (m)                                        

  **16**   27.0, CH~2~    1.32 (m)\                       29.9, CH~2~    1.26 (m)
                          1.94 (m)                                       

  **17**   50.1, CH       1.65 (m)                        52.7, CH       1.48 (m)

  **18**   16.5, CH~3~    0.66 (s)                        21.9, CH~3~    0.81 (s)

  **19**   18.4, CH~3~    1.48, s                         13.1, CH~3~    0.75 (s)

  **20**   35.6, CH       1.43 (m)                        36.0, CH       1.37, m

  **21**   18.8, CH~3~    0.93 (d, *J* = 6.5 Hz)          18.3, CH~3~    0.87 (d, *J* = 7.4 Hz)

  **22**   34.7, CH~2~    1.16 (m)\                       31.8, CH~2~    1.27 (m)\
                          1.59 (m)                                       1.42 (m)

  **23**   31.2, CH~2~    1.88 (m)\                       28.1, CH~2~    1.67 (m)\
                          2.13 (m)                                       1.95 (m)

  **24**   156.5, C                                       90.1, CH       4.21 (t, *J* = 8.0 Hz)

  **25**   33.8, CH       2.23 (m)                        143.8, C       

  **26**   21.9, CH~3~    1.03 (d, *J* = 6.8 Hz)          114.2, CH~2~   5.02 (m)

  **27**   22.0, CH~3~    1.02 (d, *J* = 6.7 Hz)          17.1, CH~3~    1.73 (s)

  **28**   106.2, CH~2~   4.66 (d, *J* = 1.2 Hz)\         27.2, CH~3~    0.98 (s)
                          4.72 (d, *J* = 0.9 Hz)                         

  **29**   16.2, CH~3~    0.95 (d, *J* = 6.2 Hz)          14.7, CH~3~    0.86 (s)

  **30**   19.6 CH~3~     1.21 (s)                        27.7, CH~3~    0.98 (s)
  ------------------------------------------------------------------------------------------------------
